EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 10th, 2017 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDMENT NO. 1 TO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (FOR NON- SMALL CELL LUNG CANCER STUDY WITH EXPANSION COHORTS IN NON-SMALL CELL LUNG CANCER, MELANOMA, AND COLORECTAL CANCER)And Supply Agreement • August 10th, 2017 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 to the CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Amendment No. 1”), made as of April 26, 2017 (the “Amendment Effective Date”), is entered into by and between Merck Sharp & Dohme B.V., having a place of business at Waarderweg 39, 2031 BN Haarlem, Netherlands, and MSD International GmbH, having a place of business at Weystrasse 20, 6000 Luzern 6, Switzerland (together, “Merck”), and Syndax Pharmaceuticals, Inc., having a place of business at 35 Gatehouse Drive, Building D, Floor 3, Waltham, MA 02451 (“Syndax”). Merck and Syndax are each referred to herein individually as a “Party” and collectively as the “Parties”.
